Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1
Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), William Y. Go(Amgen (United States)), Patrick J. Stiff(Loyola University Medical Center), Januario E. Castro(La Jolla Alcohol Research), Frederick L. Locke(Moffitt Cancer Center), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Ira Braunschweig(The University of Texas MD Anderson Cancer Center), Yizhou Jiang(University of Pennsylvania), Jeff Aycock(Moffitt Cancer Center), Caron A. Jacobson(Dana-Farber Cancer Institute), Jonathan W. Friedberg(University of Rochester), Olalekan O. Oluwole(Vanderbilt University), Meg Elias(Moffitt Cancer Center), Lynn Navale(Moffitt Cancer Center), Abhinav Deol(Wayne State University), Krishna V. Komanduri(University of Miami), Adrian Bot(Unknown), John M. Timmerman(Sheba Medical Center), Lazaros J. Lekakis(University of Miami Hospital), Nancy L. Bartlett(Washington University in St. Louis), Patrick M. Reagan(University of Rochester), Irit Avivi(Tel Aviv Sourasky Medical Center), David B. Miklos(Stanford University), Eric D. Jacobsen(Dana-Farber Cancer Institute), Ronald Levy(Hôpital Necker-Enfants Malades), Julio C. Chávez(Moffitt Cancer Center), Armin Ghobadi(Washington University in St. Louis), Mitchell R. Smith, André Goy(Hackensack University Medical Center), Javier Muñoz(The University of Texas MD Anderson Cancer Center), Yi Lin, Jeff Wiezorek(Kite (United States)), Umar Farooq(Wake Forest University), Peter A. McSweeney(Mesoblast (United States)), Ian W. Flinn(Tennessee Oncology), John M. Rossi(Amgen (United States)), Tanya Siddiqi(City Of Hope National Medical Center)
Cited by 51
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k